Tag: GlobeNewswire

SHENZHEN, China, Oct. 05, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (NASDAQ: JZXN) today provided a comprehensive update on the latest strategic positioning and future commercial prospects of its AI smart imaging and data platform. The Company confirmed that the platform is accelerating its evolution toward a unified, modular, and scalable enterprise-grade solution, with the potential for broad commercial deployment across multiple high-value scenarios, including smart retail, intelligent security, media content management, remote inspection, and advanced driver assistance. The Company maintains its guidance of approximately US1.55 million, would represent a fundamental reshaping of its revenue structure.

Platform Positioning Upgrade: From AI Recognition Module to Enterprise-Grade Infrastructure

Jiuzi Holdings’ AI smart imaging platform is completing a fundamental leap in capabilities. According to the Company’s strategic plan, the platform will no longer be a standalone image recognition tool, but a unified solution covering the entire workflow from data collection and algorithm processing to scenario applications and business decision support. This architecture deeply integrates multi-layered data structures and algorithmic capabilities, enabling the platform to transform complex image data into actionable business insights, helping customers improve operational efficiency and unlock additional value from their data assets.

Hongye Zhang, Chief Executive Officer of Jiuzi, said: “By working closely with professional AI technology partners, we will significantly enhance the technical depth and scenario adaptability of our smart imaging and data solutions, delivering more efficient, secure, and implementable AI services to global markets.” Management further noted that as the platform’s capabilities continue to evolve, the AI smart imaging system is expected to achieve broader customer adoption in North America and global markets, supporting commercialization across multiple industry scenarios.

Future Outlook: Multi-Scenario Coverage and Global Market Expansion

Looking ahead to the commercial form of the platform once mature, Jiuzi Holdings is systematically evaluating its application potential across multiple core industries. In smart retail, the platform is expected to help retailers optimize inventory management and customer experience through real-time image recognition and dynamic scenario analysis. In intelligent security, the platform’s multimodal data fusion and automated content tagging capabilities can support more efficient real-time monitoring and alert systems. In addition, the Company is working with technology partners to explore image data authentication, copyright protection, and distributed storage products in Web3 and blockchain infrastructure, preparing for future decentralized application scenarios.

At the technical deployment level, Jiuzi is focused on optimizing standardized interfaces and solution architecture, with the goal of enabling lower integration barriers and shorter deployment cycles when delivering the platform to enterprise customers, thereby accelerating the transition from pilot validation to large-scale commercial deployment. The Company believes that enterprise demand for smart imaging systems is shifting from validation of single algorithm functions to scalable, compliance-ready integrated platform architectures, and this trend is the core rationale behind Jiuzi’s platform strategy.

Million-Dollar Profit Expectation Anchors Commercial Value; Market Growth Provides Long-Term Support

Jiuzi Holdings previously disclosed that, subject to the formal advancement of relevant business arrangements, the initial stage is expected to contribute approximately US1.55 million, if realized, this profit magnitude would have a fundamental impact on the Company’s overall financial condition. Zhang noted: “If the expected profit contribution from the initial cooperation stage is realized, it will fully demonstrate the commercial potential of our AI strategy and provide an important foundation for the expansion of subsequent projects.”

From the broader market perspective, Jiuzi’s platform commercialization path has solid industry growth support. The global AI image recognition market is expected to grow from approximately US11.07 billion in 2031, representing a compound annual growth rate of approximately 14.31%. Meanwhile, the AI imaging software and services sector is experiencing rapid growth, with the AI vision software subsegment expected to reach approximately US$23.6 billion by 2032, growing at a CAGR of approximately 19.9%. As digital infrastructure upgrades accelerate, enterprise demand for smart imaging systems is shifting from experimental validation to large-scale deployment, and Jiuzi’s platform-level positioning is closely aligned with this industry trend.

AI Roadmap Progresses Clearly; Commercialization Inflection Point Approaches

Reviewing the pace of Jiuzi Holdings’ AI strategy: in May 2026, it completed the establishment of a technical cooperation framework; in June 2026, it confirmed platform milestone progress; in July 2026, it clarified its million-dollar profit expectation; and in September 2026, it advanced system validation and commercial deployment preparation. These milestones demonstrate that the Company is advancing its AI business in a phased, prudent, and steady manner. As the platform architecture continues to improve and its multi-scenario adaptability strengthens, Jiuzi’s AI smart imaging platform is establishing a solid technical and operational foundation for entering the scenario-based deployment stage with its first enterprise customers, and the million-dollar initial profit target will face substantive testing.

About Jiuzi Holdings, Inc.

Jiuzi Holdings, Inc. is a Chinese company primarily engaged in the new energy vehicle retail business. It operates “Jiuzi”-branded stores, selling battery electric vehicles and plug-in hybrid electric vehicles, and is also involved in the franchising of new energy vehicle retail stores. The Company is actively expanding its technology business footprint through strategic initiatives such as its AI smart imaging and data platform, driving diversified upgrading of its business structure.

Forward-Looking Statements

The platform development prospects and expected commercialization profits in this press release are subject to multiple conditions, including technology validation results, the actual advancement of business arrangements, project implementation, customer acceptance, and collection of payments. The Company cannot guarantee that the platform will complete all technical assessments as expected, that relevant business arrangements will proceed as planned, that the initial profit target will be achieved, or that the platform will enter the large-scale commercial deployment stage within the expected timeframe. The ultimate deployment scale, customer adoption, and commercial contribution of the AI smart imaging platform will depend on technological progress, market demand, partners’ execution capabilities, project implementation, and other commercial factors.

Media Contact:

coco@jzxn.com 

Project will deliver high-speed connectivity to public institutions and communities

PETAH TIKVA, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its Peruvian subsidiary, Gilat Perú, has signed a $28 million agreement with Pronatel (Programa Nacional de Telecomunicaciones), Peru’s national telecommunications program, to upgrade broadband connectivity across the Ica region. The project’s construction is expected to be completed by mid-year 2027 followed by a seven-year operational phase.

The Ica project marks the fifth region in Peru to receive a broadband network upgrade since 2025. The upgraded network will deliver internet speeds 20 times faster than those currently available to 116 public institutions across the Ica region and provide free Wi-Fi access in 30 public squares. The upgrade will strengthen the network’s capacity to meet the connectivity needs of institutions across different locations and operating environments and support their ability to access and deliver essential digital services, including education, healthcare, and public safety. The improved network infrastructure will also provide a stronger foundation for institutions to meet the region’s evolving connectivity needs.

“This project to increase connectivity speeds in Ica will strengthen connectivity for public institutions and expand free internet access for citizens. Through PRONATEL, the Ministry of Transport and Communications continues to advance initiatives aimed at translating greater connectivity capacity into better services and opportunities for people, helping to bridge the digital divide,” said Rafael Arias Velarde, Executive Director of PRONATEL.

“Strong connectivity is essential to enabling public institutions and communities to access digital services and opportunities,” said Arieh Rohrstock, President, Gilat Perú. “Gilat Perú has built this expertise through years of deploying, upgrading and operating large-scale networks across the country. We are proud to bring that experience to Ica, strengthening the infrastructure that connects public institutions and expanding internet access for communities across the region.”

The project builds on Gilat Perú’s extensive experience deploying, upgrading and operating large-scale telecommunications networks across the country, including in rural and geographically diverse areas. Its capabilities across the lifecycle of regional networks, from deployment and modernization to ongoing operation, enable Gilat Perú to address different geographic and operational requirements and manage large-scale connectivity infrastructure across diverse environments.

About Gilat

Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With over 35 years of experience, we develop and deliver deep technology solutions for satellite, ground, and new space connectivity, offering next-generation solutions and services for critical connectivity across commercial and defense applications. We believe in the right of all people to be connected and are united in our resolution to provide communication solutions to all reaches of the world.

Together with our wholly owned subsidiaries Gilat Wavestream, Gilat DataPath, and Gilat Stellar Blu, we offer integrated, high-value solutions supporting multi-orbit constellations, Very High Throughput Satellites (VHTS), and Software-Defined Satellites (SDS) via our Commercial and Defense Divisions. Our comprehensive portfolio is comprised of a software-defined platform and modems, high-performance satellite terminals, advanced Satellite On-the-Move (SOTM) antennas and Electronically Steered Antennas (ESAs), highly efficient, high-power Solid State Power Amplifiers (SSPA) and Block Upconverters (BUC) and includes integrated ground systems for commercial and defense markets, field services, network management software, and cybersecurity services.

Gilat’s products and tailored solutions support multiple applications including government and defense, IFC and mobility, cellular backhaul, enterprise, aerospace and critical infrastructure clients all while meeting the most stringent service level requirements. For more information, please visit: https://www.gilat.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and can generally be identified by the use of forward-looking terminology such as “estimate,” “project,” “intend,” “expect,” “believe,” “anticipate,” “plan,” “may,” “will,” “seek,” “could,” “should,” or similar expressions. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements of Gilat to differ materially from those expressed in, or implied by, such statements. These risks and uncertainties include, among others, changes in general economic, market and business conditions; failure to maintain market acceptance of Gilat’s products; failure to timely develop and introduce new technologies, products and applications; rapid changes in the markets in which Gilat operates; increased competition, loss of market share or pressure on prices; loss of key OEM partners; inability to attract and retain qualified personnel; inability to protect proprietary technology; and risks associated with Gilat’s international operations and its location in Israel, including those arising from regional military conflicts and geopolitical instability. For additional information regarding these and other risks and uncertainties, please refer to Gilat’s filings with the U.S. Securities and Exchange Commission. Gilat undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Gilat Satellite Networks
Hagay Katz, Chief Products and Marketing Officer
PublicRelations@gilat.com

Phased Production Model with Staggered Rearing Schedules Keeps Operations Running Continuously, Positioning Kraig Labs to Meet Future Commercial Demand

ANN ARBOR, Mich., Oct. 05, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that its September/October production cycle is well underway, with all three production centers running. Early reports indicate the Company is on track for another successful rearing cycle.

The announcement comes just days after Kraig Labs fulfilled its first purchase order from the performance sportswear segment, shipping custom recombinant spider silk yarn to a globally recognized brand. That delivery marked the Company’s transition from production milestones to commercial deliveries. This last cycle is further evidence of the production engine behind that milestone. Kraig Labs has built a reliable production platform capable of sustaining commercial-scale levels of spider silk to the market.

“Our team in Vietnam is executing well, and the early indicators for this cycle are encouraging,” said Kim Thompson, Founder and CEO of Kraig Labs. “All three centers are up and running on schedule. That matters now, more than ever. We are no longer producing to demonstrate and confirm scale. Production is now focused on addressing the commercial market opportunities for spider silk.”

Kraig Labs uses genetically engineered silkworms to produce silk containing key spider silk proteins. A “rearing cycle” involves raising a batch of silkworms from hatching through cocoon formation. The current cycle focuses on the Company’s parental strains, which are the breeding lines used to produce hybrid silkworm eggs. Silkworms hatched from those eggs subsequently produce the silk cocoons that are processed into yarn.

“Running three centers on phased schedules isn’t just about volume,” Thompson continued. “It’s about building an operation that is resilient at high volume. One center can be in early rearing while another is deep into production and a third is preparing for harvest. That overlap gives us continuous output and real redundancy. If one center faces a disruption, the other two keep moving.”

Kraig Labs’ three production centers each run their own rearing cycle on a staggered schedule, so the facilities are at different stages of development at any given time. This approach maintains a steady supply of hybrid eggs for subsequent silk production while reducing reliance on any single facility.

That redundancy has taken on added significance following the Company’s last production run. Kraig Labs grew silk production by more than 30% through the rainy season, historically one of the most difficult stretches of the year. Management believes the phased model was a key factor behind that result. This system continues to elevate Kraig’s operations with a growing supply line of spider silk available to address opportunities for additional commercial orders.

Thompson concluded, “A continuous, redundant production model is what positions Kraig Labs to move quickly when new opportunities arise. Three centers, three schedules, one continuous operation, prepared for the opportunities ahead.”

The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

You can see Kraig Labs featured in Veritasium’s spider silk video at https://www.youtube.com/watch?v=wt4p2oalmRY

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ab747743-744f-4ffd-bac0-9d6cad3dabec

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate 

Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3

MELBOURNE, Australia and SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that additional analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) were presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Seoul, Korea. The poster brings together clinical, biomarker, and imaging results from the trial after adjusting for baseline disease severity, measured by cerebrospinal fluid neurofilament light chain (CSF NfL).

“These additional analyses strengthen our confidence in ATH434 as a potential disease-modifying therapy for MSA. When we account for differences in baseline disease severity using CSF NfL, ATH434 50 mg significantly slowed functional decline by more than 50% compared with placebo over one year, a treatment effect well above the threshold considered clinically meaningful,” said David Stamler, M.D., CEO.

“I continue to be impressed by the strength of the efficacy signal in our Phase 2 study in the context of other treatments that are in development for MSA. By incorporating the learnings regarding NfL into our Phase 3 confirmatory trial, we continue to build on our de-risking strategy that has been so successful in Phase 2,” concluded Dr. Stamler.

The poster, entitled, “ATH434 in Multiple System Atrophy: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study with CSF Neurofilament Light Chain as a Disease Severity Covariate,” analyzed baseline CSF NfL, an established prognostic biomarker of clinical decline in MSA, as a covariate to account for variability in baseline disease severity.

The analysis demonstrated that CSF NfL, a prespecified covariate in the Phase 2 trial, predicts functional decline in individuals with MSA. Higher baseline CSF NfL predicted greater decline at Week 52: each 1,000 pg/mL increase was associated with approximately 0.9 additional points of worsening on UMSARS I¹, an effect that was significant (p=0.033). This supports using CSF NfL as a covariate in future MSA trials since adjusting for a known predictor of decline can produce a more precise measurement of treatment effect.

ATH434 50 mg significantly slowed functional decline on the 11-item UMSARS Part I

The analysis utilized a mixed model for repeated measures (MMRM)² applied to align with the imaging analyses conducted on the Modified Intent-to-treat (mITT) population (N=61)³. After adjustment for baseline CSF NFL, ATH434 50 mg significantly slowed functional decline on the 11-item UMSARS Part I⁴ at Week 52 with a −4.64-point difference versus placebo in change from baseline (p=0.032), roughly 3-fold more improvement compared to the 1.5-point minimal clinically important difference (MCID). This represents an approximate 52% slowing of functional decline in the 50 mg dose group relative to placebo. The 75 mg dose also slowed functional decline with a −2.81-point difference versus placebo in change from baseline at Week 26 (p=0.072) and Week 52 (p=0.179). These results are consistent with the previously reported analysis of the 11-item UMSARS Part I in the Phase 2 clinical analysis population, in which ATH434 50 mg slowed decline by 46% versus placebo (p=0.037). The difference between the two figures reflects the distinct analysis populations and statistical models.

Advanced brain iron MRI imaging is consistent with the ATH434 mechanism of action as an iron-chaperone

The poster also reported brain iron measured by quantitative susceptibility mapping (QSM) MRI analyzed with the same CSF NfL-adjusted model. ATH434 is designed as an iron chaperone and is intended to redistribute reactive (labile) iron that is driving MSA pathology. MRI can detect iron leaving cells but cannot measure iron that has been stored or buffered within cells. Although the trial’s primary endpoint of change in substantia nigra iron at Week 52 was not met, change from baseline in iron was numerically lower in the putamen and globus pallidus with ATH434 vs placebo. In the dentate nucleus, iron signal increased relative to placebo at Week 52 (50 mg: +0.016 ppm, p=0.021), which is hypothesized to reflect redistribution of mobilized iron through the brain’s glymphatic system. The poster noted that regional differences may reflect region-specific iron handling because an MRI captures iron efflux but not the potential storage or buffering effects of ATH434.

The presentation is available on the Alterity Therapeutics website here.

About ATH434-201 Phase 2 Clinical Trial 

The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy, safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or 75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 50 mg produced clinically and statistically significant slowing of decline on the 11-item Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, a functional rating scale that assesses disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the positive UMSARS Part I findings including trends in improved motor performance on the Clinical Global Impression of Severity Scale, the Swallowing Disturbance Questionnaire and the Orthostatic Hypotension Symptom Assessment. Wearable sensor data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect and target engagement relative to placebo. Both dose levels reduced iron accumulation in MSA affected brain regions with trends in preservation of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091.

About Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects up to 50,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.⁴

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

References:
¹ UMSARS: 11-item Unified Multiple System Atrophy Rating Scale Part I (excludes sexual function)
² Mixed Models for Repeated Measures (MMRM) analysis using all visits without imputation (treatment, visit, treatment-by-visit interaction, sex; covariates age, baseline score, baseline CSF NfL), added post hoc to align with the imaging analyses; the prespecified analysis was a Week 52 Analysis of Covariance (ANCOVA).
³ Modified Intent-to-treat (mITT) population (N=61): randomized and dosed, CSF α-synuclein seed amplification assay positive, with ≥1 postbaseline QSM assessment.
⁴ Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors
Elyse Shapiro
ir@alteritytx.com

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au

Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

Schindellegi, Switzerland – 5 October 2026

Trifork Group AG
Company announcement no. 61/2026

Weekly report on share buyback

On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026.

Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million).

Under the program, the following transactions have been made:

Date	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Total beginning	532,184	100.00	53,216,166
28 September 2026	3,500	102.00	357,000
29 September 2026	3,600	101.42	365,112
30 September 2026	3,600	101.39	365,004
1 October 2026	3,500	101.09	353,815
2 October 2026	1,693	101.02	171,027
Accumulated	548,077	100.04	54,828,124

A detailed overview of the daily transactions can be found here: https://investor.trifork.com/trifork-shares/.

With the transactions stated above, the total accumulated amount of treasury shares acquired under the current share buyback program corresponds to 2.8% of the share capital of Trifork Group AG. Trifork Group owns 814,493 treasury shares in total, corresponding to 4.1% of the share capital.

Investor & Media contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 7317

About Trifork Group
Trifork (Nasdaq Copenhagen: TRIFOR) is a global technology company specializing in designing, building, and operating advanced software for enterprise and public sector customers. With 1,118 FTEs across 16 countries, Trifork serves as an end-to-end technology partner to organizations in complex and regulated industries, including public administration, healthcare, financial services, energy, and aviation.
Learn more at trifork.com.

Attachment

• CA_61_2026_Buyback

NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. 

The options have a per share exercise price of $0.8165, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan. 

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts: 

Media Relations 
(781) 208-0160 
media@invivyd.com 

Investor Relations 
(781) 208-1747 
investors@invivyd.com 

Heineken N.V. reports the progress of transactions under its current
share buyback programme

Amsterdam, 5 October 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 28 September 2026 up to and including 2 October 2026 a total of 167,000 shares were repurchased on exchange at an average price of € 70.02. During the same period, 164,528 shares were repurchased from Heineken Holding N.V.

Up to and including 2 October 2026, a total of 8,178,632 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 580,102,339 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries

Media			Investors
Christiaan Prins			Tristan van Strien
Director of Global Communication			Global Director of Investor Relations
Marlie Paauw			Lennart Scholtus / Isabelle van Rongen
Global Media Lead			Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com			E-mail: investors@heineken.com
Tel: +31-20-5239355			Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

• PR_SBB 2025_Weekly update_05-Oct-2026

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today announced the appointment of Garzon Duenas as General Manager and Commissioning Leader, effective today. The appointment strengthens Electra’s operating leadership as the Company prepares to transition its Ontario cobalt sulfate refinery from construction through commissioning, ramp-up and commercial operations.

Construction remains on budget, with select commissioning activities targeted to begin in the fourth quarter of 2026, mechanical completion targeted for the second quarter of 2027, full commissioning and production ramp-up expected in the third quarter of 2027, and commercial production targeted for the fourth quarter of 2027.

Mr. Duenas holds a Bachelor of Science in Metallurgical Engineering and brings more than three decades of experience managing, commissioning and operating mineral processing plants and refining facilities in Canada and internationally. His background spans cobalt, nickel, copper, platinum group metals, gold and specialty chemicals, with extensive experience in operational readiness, process optimization, team development and the safe transition of processing facilities into production.

“With mechanical completion targeted for the second quarter of 2027, we are now building the team and operating systems needed to commission the refinery and bring it into production safely and reliably,” said Trent Mell, CEO. “Garzon and I have worked together before, and I have seen firsthand the discipline and operating focus he brings. He sets high performance standards, drives continuous improvement and develops the people around him to deliver against those standards. I know what he can deliver and I am confident he is the right leader to help take the refinery from construction through commissioning and into operations.”

As Electra’s General Manager, Mr. Duenas will lead operational readiness and the transition of the Company’s refinery from construction through commissioning, start-up and into steady-state operations. He will be responsible for building and leading the commissioning and operating teams, establishing the systems, procedures and operating discipline required for safe and reliable production, and working closely with the project team to ensure a seamless transition from construction to operations.

During his career, Mr. Duenas managed the commissioning and start-up of a 3,000-tonne-per-year nickel and cobalt processing facility in the Philippines that produced high-purity nickel and cobalt salts using leaching and solvent extraction, both core unit operations in Electra’s refinery. He later served as project manager for the engineering, procurement and construction management of a nickel refinery and led the commissioning of a nickel concentrator through to commercial production. He has also overseen concentrator operations of up to 20,000 tonnes per day, water-treatment systems, maintenance programs, operating budgets and continuous-improvement initiatives.

Most recently, Mr. Duenas led mill and surface operations at Eldorado Gold Saskatchewan, where his responsibilities included production management, operational readiness and commissioning, as well as coordinating engineering teams, contractors and operating personnel ahead of start-up. He previously oversaw mill operations at North American Palladium’s Lac des Iles mine in northwestern Ontario, where he is credited with improving recoveries and overall operations for a 15,000 tonne-per-day mill and has also held senior operational and process-management roles with Myra Falls Mine, Canadian Silica Industries, Westpro Machinery and other mineral-processing organizations.

“Electra is at an important point in the development of the refinery, and I’m excited to join the team as we prepare to make the transition into operations,” said Mr. Duenas. “Earlier in my career I commissioned nickel and cobalt leaching and solvent-extraction circuits, and I know that a successful start-up is largely decided before the first feed is introduced. My focus will be on creating a strong operating culture built around safety, reliability and execution, and ensuring our people and processes are ready to deliver as the refinery comes online.”

Electra’s refinery in Temiskaming Shores, Ontario, is designed to process approximately 18,000 tonnes of cobalt hydroxide feed per year to produce 5,120 tonnes per year of contained cobalt in a battery-grade cobalt sulfate. A Phase 2 expansion will increase cobalt-hydroxide throughput to approximately 22,500 tonnes per year, or 68 tonnes per day, to produce 6,500 tonnes per year of contained cobalt. Once commissioned, the facility is expected to be North America’s first battery-grade cobalt sulfate refinery, providing a domestic source of refined cobalt and adding to the continent’s critical minerals processing supply chain. The refinery is expected to be a cornerstone of Electra’s broader strategy to build a potential North American critical minerals processing platform and reduce reliance on foreign refining capacity.

The Company also announces that in accordance with its Long-Term Incentive Plan, and in connection with this appointment, the Company will issue 150,000 incentive stock options, adjusted for the closing price as of October 5, 2026. The stock options will vest in two equal tranches on the first and second anniversary of the grant date over a three-year period. The grant is subject to the approval of the TSX Venture Exchange. Long-term incentive grants are an important retention and incentive tool for key employees, and a mechanism to align interests with shareholders.

About Electra Battery Materials

Electra is a leader in advancing North America’s critical minerals supply chain for lithium-ion batteries. The Company’s primary focus is constructing North America’s first battery-grade cobalt sulfate refinery, as part of a phased strategy to onshore critical minerals refining and reduce reliance on foreign supply chains. In addition to the refinery, Electra holds a significant land package in Idaho’s Cobalt Belt, including its Iron Creek project and surrounding properties, positioning the Company as a potential cornerstone for North American cobalt and copper production.

Electra is also advancing black mass recycling opportunities to recover critical materials from end-of-life batteries, while continuing to evaluate growth opportunities in nickel refining and other downstream battery materials. For more information, please visit www.ElectraBMC.com.

Contact
Heather Smiles
Vice President, External Affairs & Corporate Development
Electra Battery Materials
info@ElectraBMC.com
1.416.900.3891

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements, including statements relating to the anticipated timing of mechanical completion, commissioning, ramp-up and commencement of operations at the refinery; expected production capabilities; anticipated economic, employment and supply-chain benefits; and the Company’s financing plans, strategic objectives, business plans, future operations and growth opportunities. Generally, forward-looking statements can be identified by the use of terminology such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved” or similar expressions and are based on current assumptions and expectations. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, and opportunities to differ materially from those implied by such forward-looking statements. Although Electra Battery Materials Corporation believes that the information and assumptions used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, Electra Battery Materials Corporation disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Factors that could cause actual results to differ materially from these forward-looking statements are set forth in the management discussion and analysis and other disclosures of risk factors for Electra Battery Materials Corporation, at www.sedarplus.com and on EDGAR at www.sec.gov.

Two-year extension builds on productive relationship established in 2019

Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States

BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an additional two years. This is the second two-year extension of the research term for this program.  

“Gilead’s decision to extend the research term for this program reflects our longstanding commitment to productive collaborations, the outstanding dedication of our research teams, and the potential of Nurix’s targeted protein degradation platform to generate novel medicines against therapeutically important targets,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “Our collaboration has already advanced GS-6791, an oral IRAK4 degrader discovered by Nurix, into clinical development, and we are pleased to continue working with Gilead to discover and advance additional drug candidates across oncology and inflammatory diseases. This extension provides further evidence of the value of the collaboration and the capabilities of our platform.”

Under the collaboration agreement, originally established in 2019, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license drug candidates resulting from the collaboration, and Nurix retains options for 50/50 profit and loss sharing for development, commercialization, and co-detailing on up to two programs in the United States, subject to certain restrictions. For programs in which Nurix exercises its option, the parties will share U.S. development costs as well as profits and losses 50/50, and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments.

In connection with today’s announcement, Nurix will receive a $10 million research term extension fee under the amended collaboration agreement. As of May 31, 2026, Nurix is eligible to receive up to approximately $1.3 billion in total payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones. Nurix is also eligible to receive mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products. The first program licensed by Gilead under this agreement, GS-6791 (NX-0479), is a potent, selective, oral IRAK4 degrader which is now in Phase 1 clinical development.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s expectations for its collaboration with Gilead Sciences; the potential benefits of Nurix’s collaboration with Gilead Sciences; the potential benefits of the research term extension for the undisclosed oncology program; the potential achievement of milestone, royalty and license payments; and the potential advantages of Nurix’s scientific approach and DEL-AI platform. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes such expectations and assumptions are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Gilead collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Gilead collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Gilead collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media and Investors
Kris Fortner
Nurix Therapeutics, Inc.
ir@nurixtx.com

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise

NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA^® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Viatris retained the rights to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to TYRVAYA’s net sales, for potential total consideration of up to $100 million. The closing payment was funded with cash on hand.

TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is the first and only FDA-approved nasal spray for DED. Unlike topical ophthalmic therapies, TYRVAYA is administered through the nose and is thought to activate the trigeminal parasympathetic pathway to stimulate basal tear production. TYRVAYA is approved in the U.S., China, and Taiwan, with marketing applications pending in additional markets.

The addition of TYRVAYA meaningfully expands Harrow’s position in the large and growing U.S. dry eye market and complements VEVYE^®, Harrow’s flagship prescription therapy for DED. With two highly differentiated branded prescription products, Harrow believes it can give eyecare professionals greater flexibility to individualize treatment based on their patients’ needs and preferences.

“Today marks an important step forward for Harrow and for the physicians and patients we serve,” said Mark L. Baum, Chief Executive Officer of Harrow. “Dry eye disease is complex and multifactorial, and there is no single treatment approach that works for every patient. VEVYE and TYRVAYA approach dry eye differently and give eyecare professionals two distinct tools from one organization committed to serving this market. VEVYE remains the cornerstone of our dry eye franchise, while TYRVAYA gives us an established, complementary prescription brand with a unique route of administration and an existing base of physicians who know and use the product.”

Baum added, “We see a significant commercial opportunity ahead. TYRVAYA comes to Harrow with meaningful physician awareness, an established prescription base, and years of real-world clinical experience. By combining that foundation with Harrow’s expanding Ocular Surface commercial organization, market access capabilities, and focus on patient access and affordability, we believe we can introduce TYRVAYA to many more eyecare professionals and patients while also expanding awareness of VEVYE among existing TYRVAYA prescribers.”

Expanding Harrow’s Ocular Surface Commercial Platform

TYRVAYA will be available to eyecare professionals through Harrow’s commercial organization immediately after closing. As part of the acquisition, Harrow expects approximately 40 experienced personnel from Viatris, with established knowledge of TYRVAYA and the dry eye market, to join and augment Harrow’s existing Ocular Surface commercial team. Harrow expects to onboard these new colleagues during the fourth quarter of 2026. Harrow’s expanded Ocular Surface team will support both VEVYE and TYRVAYA as the integration progresses.

Harrow believes the combination of two differentiated dry eye brands and a larger, experienced field organization create several attractive commercial opportunities:

• Expanded prescriber reach: The approximately 40 personnel expected to join Harrow will materially increase the size of Harrow’s Ocular Surface team, expanding its reach and frequency of engagement with ophthalmologists and optometrists who manage dry eye disease.
• Broader portfolio engagement: TYRVAYA brings an established prescriber base and meaningful familiarity among eyecare professionals. Bringing VEVYE and TYRVAYA together creates opportunities to deepen engagement across both brands and expand utilization across Harrow’s dry eye portfolio.
• Commercial efficiency: Both VEVYE and TYRVAYA utilize PhilRx as their primary specialty pharmacy and will be supported by a single Ocular Surface commercial organization, allowing Harrow to leverage shared commercial, market access, patient-support, and operational infrastructure across both brands.

Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027. With commercial integration beginning in the fourth quarter of 2026, Harrow believes TYRVAYA’s established prescription base, physician awareness, and experienced commercial team, combined with Harrow’s dedicated Ocular Surface infrastructure, provide a strong foundation for growth in 2027 and beyond.

“TYRVAYA is a product I have used extensively in my dry eye practice, and its nasal route of administration makes it a truly differentiated treatment option,” said Laura Periman, MD, a board-certified ophthalmologist at Periman Eye Institute. “For patients who struggle with eye drops or contact lens wearers who want an option that does not require removing their lenses, TYRVAYA can fit very well into their treatment routine. I have seen firsthand the value of stimulating a patient’s own tear production, and I am pleased to see TYRVAYA become part of Harrow, a company deeply committed to eyecare and patient access.”

“VEVYE has become an important option in my dry eye practice because of the clinical benefits it can provide, and TYRVAYA is another therapy I know well and have prescribed for years,” said Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute. “The two products approach dry eye very differently: VEVYE is applied directly to the ocular surface, while TYRVAYA is administered nasally and stimulates natural tear production through a distinct mechanism. Having therapies with different mechanisms and routes of administration gives me greater flexibility to individualize treatment based on each patient’s needs. I’m pleased to see both products together at Harrow, giving physicians more options for patients with this chronic disease.”

Eyecare professionals can send TYRVAYA prescriptions using their electronic medical record (EMR) software directly to Harrow’s dedicated pharmacy partner, PhilRx. Prescriptions can also be sent to any retail pharmacy. TYRVAYA is fully stocked in the wholesale distribution channel, including McKesson, Cardinal, and Cencora, and can be shipped to any retail pharmacy, generally within 24 hours of order placement.

Interested patients should ask their trusted eyecare professional whether TYRVAYA and VEYVE are right for them.

VEVYE^® (cyclosporine ophthalmic solution) 0.1%

INDICATIONS AND USAGE
VEVYE^® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.

Use with Contact Lenses: VEVYE^® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE^®.

ADVERSE REACTIONS
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE^®, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

Please see full Prescribing Information for VEVYE.

TYRVAYA^® (varenicline solution) nasal spray 0.03 mg

INDICATIONS AND USAGE
TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information
ADVERSE REACTIONS
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5–16% of patients were cough, throat irritation, and instillation-site (nose) irritation.

Please see full Prescribing Information for TYRVAYA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of this acquisition and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contact:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890